{"id":619,"date":"2019-11-07T08:36:33","date_gmt":"2019-11-07T14:36:33","guid":{"rendered":"http:\/\/viceroyresearch.org\/?p=619"},"modified":"2020-12-16T14:29:17","modified_gmt":"2020-12-16T14:29:17","slug":"athenex-2019-q3-financials-brief","status":"publish","type":"post","link":"https:\/\/viceroyresearch.org\/2019\/11\/07\/athenex-2019-q3-financials-brief\/","title":{"rendered":"Athenex &#8211; 2019 Q3 Financials Brief"},"content":{"rendered":"<p>Falling revenues, stalled operations, flat R&amp;D.<\/p>\n<p><a title=\"Viceroy Research - Athenex Q3 Brief - 7 Nov 2019\" href=\"https:\/\/viceroyresearch.org\/wp-content\/uploads\/2019\/11\/viceroy-research-athenex-q3-brief-7-nov-2019.pdf\">DOWNLOAD BRIEF<\/a><\/p>\n<p><strong>November 7, 2019<\/strong> \u2013 This report is a brief on Athenex\u2019s Q3 results announcement. Viceroy will provide a further, more in depth update upon the release of Athenex\u2019s 10-Q.<\/p>\n<ul>\n<li>Athenex revenues continue to fall Q\/Q, and has guided to do so in Q4, despite Athenex\u2019s raised guidance. This is primarily due to higher than anticipated sales in Q1 &amp; Q2 for Vasopressin, which has been pulled due to FDA ruling brought about by a lawsuit against Athenex by its largest customer, AmerisourceBergen.<\/li>\n<li>Athenex COO, Jeffrey Yordon, states stated the FDA\u2019s decision regarding Vasopressin \u201cdid not come unexpected\u201d. Either this is a lie, or the Athenex had been consciously illegally selling as much Vasopressin as possible before the FDA undoubtedly came knocking.<\/li>\n<li>Address of financials persists on using YOY figures to hide the fact that the company has suffered declining revenue in the last two quarters.<\/li>\n<li>Q3 Update confirms API production is still suspended.<\/li>\n<li>Cost of sales have conversely slightly increased Q\/Q.<\/li>\n<li>R&amp;D expenditure is flat YOY, excluding one-time-costs, despite an increase in drugs in development. This suggests to us that Athenex have curbed spending.<\/li>\n<li>As previously reported, Athenex have not only <strong>committed &gt;US$1.5b<\/strong> expenditure at their Dunkirk site across the next ten years but are also <strong><u>on the hook for excess development costs for the facility<\/u><\/strong>, whose floorplan has expanded by 28% on-the-fly and falling significantly behind schedule. We are curious to see the cash burn in relation to this facility in Athenex\u2019s 10-Q.<\/li>\n<li>Athenex\u2019s new <strong><u>China-funded plant must also generate unrealistic revenues of almost US$1b within 5 years of opening, despite turning over only $160m across the last 5 years combined.<\/u><\/strong><\/li>\n<li><strong><u>There has been no change to Athenex\u2019s massive cash burn this year, with losses accelerating to $102m in the 9 months leading to Q3, 2019.<\/u><\/strong> To manage its cash burning commitments to major facilities and R&amp;D, Athenex has issued dilutive equity, and incredulously borrowed US$50m from major investor, Perceptive, at a punitive rate of 11%.<\/li>\n<\/ul>\n<p>Athenex management &#8220;stand behind the integrity of its management team and board&#8221; and will refuse to address us, according to Mr. Lau on this morning&#8217;s conference call. This is laughable considering half the board has evaporated billions in prior frauds.<\/p>\n<p>We have <em>already<\/em> highlighted <strong><u>management\u2019s involvement in Sino Forest, GCL Silicon\/Poly, Suntech, Chelsea Therapeutics, the world\u2019s largest illegal taxol smuggling operation, LyphoMed, Gensia and Sagent<\/u><\/strong>. It is mind blowing that Athenex investors would continue to associate with any one of these farces, let alone a collection such as this.<\/p>\n<p>Considering the quantum of issues Viceroy have highlighted, it is alarming to shareholders that Athenex have not addressed a single point of our work. Opting instead to simply state we have published \u201cinaccurate information\u201d. Other commentators have begun to back-test our work<a href=\"#_ftn1\" name=\"_ftnref1\"><strong>[1]<\/strong><\/a>.<br \/>\n<strong>Where are the inaccuracies, Athenex?<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>We will provide a more updated brief upon the release of Athenex\u2019s 10-Q.<\/p>\n<p><strong>Report 1: <\/strong><a href=\"https:\/\/viceroyresearch.org\/2019\/10\/22\/athenex-too-little-too-late\/\">https:\/\/viceroyresearch.org\/2019\/10\/22\/athenex-too-little-too-late\/<\/a><\/p>\n<p><strong>Report 2: <\/strong><a href=\"https:\/\/viceroyresearch.org\/2019\/10\/23\/athenex-where-theres-smoke\/\">https:\/\/viceroyresearch.org\/2019\/10\/23\/athenex-where-theres-smoke\/<\/a><\/p>\n<p><strong>Report 3: <\/strong><a href=\"https:\/\/viceroyresearch.org\/2019\/10\/24\/athenex-no-integrity\/\">https:\/\/viceroyresearch.org\/2019\/10\/24\/athenex-no-integrity\/<\/a><\/p>\n<p><strong>Report 4: <\/strong><a href=\"https:\/\/viceroyresearch.org\/2019\/10\/25\/athenex-bonus-round\/\">https:\/\/viceroyresearch.org\/2019\/10\/25\/athenex-bonus-round\/<\/a><\/p>\n<p><strong>Report 5: <\/strong><a href=\"https:\/\/viceroyresearch.org\/2019\/10\/28\/athenex-rehash\/\">https:\/\/viceroyresearch.org\/2019\/10\/28\/athenex-rehash\/<\/a><\/p>\n<p><strong>Report 6: <\/strong><a href=\"https:\/\/viceroyresearch.org\/2019\/10\/29\/athenex-unpopular-operating-officer\/\">https:\/\/viceroyresearch.org\/2019\/10\/29\/athenex-unpopular-operating-officer\/<\/a><\/p>\n<p><strong>Report 7: <\/strong><a href=\"https:\/\/viceroyresearch.org\/2019\/11\/04\/athenex-financial-situation\/\">https:\/\/viceroyresearch.org\/2019\/11\/04\/athenex-financial-situation\/<\/a><\/p>\n<p><strong>Other Coverage: <\/strong><a href=\"https:\/\/seekingalpha.com\/instablog\/38002746-denniskneale\/5369151-cancer-conflicts-interest\">https:\/\/seekingalpha.com\/instablog\/38002746-denniskneale\/5369151-cancer-conflicts-interest<\/a><\/p>\n<p><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> Blog entry-Dennis Kneale:<a href=\"https:\/\/seekingalpha.com\/instablog\/38002746-denniskneale\/5369151-cancer-conflicts-interest\">https:\/\/seekingalpha.com\/instablog\/38002746-denniskneale\/5369151-cancer-conflicts-interest<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Falling revenues, stalled operations, flat R&amp;D. DOWNLOAD BRIEF November 7, 2019 \u2013 This report is&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_links_to":"","_links_to_target":""},"categories":[81],"tags":[],"table_tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v15.6.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Athenex - 2019 Q3 Financials Brief | Viceroy Research<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/viceroyresearch.org\/2019\/11\/07\/athenex-2019-q3-financials-brief\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Athenex - 2019 Q3 Financials Brief | Viceroy Research\" \/>\n<meta property=\"og:description\" content=\"Falling revenues, stalled operations, flat R&amp;D. DOWNLOAD BRIEF November 7, 2019 \u2013 This report is...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/viceroyresearch.org\/2019\/11\/07\/athenex-2019-q3-financials-brief\/\" \/>\n<meta property=\"og:site_name\" content=\"Viceroy Research\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-07T14:36:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-16T14:29:17+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\">\n\t<meta name=\"twitter:data1\" content=\"3 minutes\">\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/viceroyresearch.org\/#organization\",\"name\":\"Viceroy Research\",\"url\":\"https:\/\/viceroyresearch.org\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/viceroyresearch.org\/#logo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/viceroyresearch.org\/wp-content\/uploads\/2020\/12\/cropped-VT-Tulip.png\",\"width\":512,\"height\":512,\"caption\":\"Viceroy Research\"},\"image\":{\"@id\":\"https:\/\/viceroyresearch.org\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/viceroyresearch.org\/#website\",\"url\":\"https:\/\/viceroyresearch.org\/\",\"name\":\"Viceroy Research\",\"description\":\"A group of individuals that see the world differently.\",\"publisher\":{\"@id\":\"https:\/\/viceroyresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/viceroyresearch.org\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/viceroyresearch.org\/2019\/11\/07\/athenex-2019-q3-financials-brief\/#webpage\",\"url\":\"https:\/\/viceroyresearch.org\/2019\/11\/07\/athenex-2019-q3-financials-brief\/\",\"name\":\"Athenex - 2019 Q3 Financials Brief | Viceroy Research\",\"isPartOf\":{\"@id\":\"https:\/\/viceroyresearch.org\/#website\"},\"datePublished\":\"2019-11-07T14:36:33+00:00\",\"dateModified\":\"2020-12-16T14:29:17+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/viceroyresearch.org\/2019\/11\/07\/athenex-2019-q3-financials-brief\/\"]}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/viceroyresearch.org\/2019\/11\/07\/athenex-2019-q3-financials-brief\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/viceroyresearch.org\/2019\/11\/07\/athenex-2019-q3-financials-brief\/#webpage\"},\"author\":{\"@id\":\"https:\/\/viceroyresearch.org\/#\/schema\/person\/38e10fc7394949cc6e1f60bbc3ac77df\"},\"headline\":\"Athenex &#8211; 2019 Q3 Financials Brief\",\"datePublished\":\"2019-11-07T14:36:33+00:00\",\"dateModified\":\"2020-12-16T14:29:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/viceroyresearch.org\/2019\/11\/07\/athenex-2019-q3-financials-brief\/#webpage\"},\"publisher\":{\"@id\":\"https:\/\/viceroyresearch.org\/#organization\"},\"articleSection\":\"Athenex NASDAQ:ATNX\",\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/viceroyresearch.org\/#\/schema\/person\/38e10fc7394949cc6e1f60bbc3ac77df\",\"name\":\"Viceroy Research\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/viceroyresearch.org\/#personlogo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0031e3f514f9d4a17ee5a39a058b5d7e?s=96&d=identicon&r=g\",\"caption\":\"Viceroy Research\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/posts\/619"}],"collection":[{"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/comments?post=619"}],"version-history":[{"count":4,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/posts\/619\/revisions"}],"predecessor-version":[{"id":4937,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/posts\/619\/revisions\/4937"}],"wp:attachment":[{"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/media?parent=619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/categories?post=619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/tags?post=619"},{"taxonomy":"table_tags","embeddable":true,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/table_tags?post=619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}